Celldex Therapeutics CLDX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Celldex Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Celldex Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Celldex Therapeutics's stock-based comp?
- Celldex Therapeutics (CLDX) reported stock-based comp of $8.52M in Q1 2026.
- How has Celldex Therapeutics's stock-based comp changed year-over-year?
- Celldex Therapeutics's stock-based comp decreased by 8.5% year-over-year, from $9.32M to $8.52M.
- What is the long-term trend for Celldex Therapeutics's stock-based comp?
- Over 4 years (2021 to 2025), Celldex Therapeutics's stock-based comp has grown at a 41.8% compound annual growth rate (CAGR), from $8.95M to $36.22M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.